News on immunohistochemistry and other tissue-based testing methods.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The La Jolla, California-based developer of genomic melanoma tests posted nearly $1.6 million in revenues in Q4, up from $600,000 in Q4 2018.
S2 Genomics' Singulator platform combines enzymatic and mechanical disruption to produce suspensions of cells or nuclei for downstream applications.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
